Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med (2016) 4.31

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet (2015) 0.96

A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov (2015) 0.85

Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk. Hum Mol Genet (2015) 0.81

Male reproductive cancers and infertility: a mutual relationship. Int J Mol Sci (2015) 0.79

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br J Cancer (2016) 0.78

Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open (2016) 0.77

Defective DNA repair mechanisms in prostate cancer: impact of olaparib. Drug Des Devel Ther (2017) 0.75

Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget (2015) 0.75

Germline Variants of Prostate Cancer in Japanese Families. PLoS One (2016) 0.75

Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact. Trans Am Clin Climatol Assoc (2017) 0.75

Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94

Global cancer statistics. CA Cancer J Clin (2011) 185.92

A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res (2010) 43.51

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 14.03

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17

Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72

dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat (2011) 6.97

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 5.60

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18

The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet (2005) 4.13

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet (2004) 3.97

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81

Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature (2013) 3.40

Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst (2005) 3.09

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71

Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res (2005) 2.16

Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96

PrimerZ: streamlined primer design for promoters, exons and human SNPs. Nucleic Acids Res (2007) 1.91

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer (2011) 1.86

Mendel: the Swiss army knife of genetic analysis programs. Bioinformatics (2013) 1.85

Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78

Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med (2012) 1.60

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60

Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet (2004) 1.58

A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol (2011) 1.58

Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer (2012) 1.45

Commentary on "identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array." Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Urol Oncol (2014) 1.42

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer (2007) 1.38

NBS1 is a prostate cancer susceptibility gene. Cancer Res (2004) 1.24

Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet (2005) 1.13

Combining target enrichment with barcode multiplexing for high throughput SNP discovery. BMC Genomics (2010) 1.12

No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. Br J Cancer (1997) 1.10

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol (2013) 1.06

ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer (2004) 1.00

Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol (1997) 0.99

Mismatch repair genes in Lynch syndrome: a review. Sao Paulo Med J (2009) 0.91

A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer. Br J Cancer (2009) 0.87

Familial association of prostate cancer with other cancers in the Swedish Family-Cancer Database. Prostate (2005) 0.85

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer (2011) 1.86

Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer (2012) 1.45

A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer. Br J Cancer (2009) 0.87